With a goal to stamp out a rare disease that takes the lives of about one-fifth of the children it affects, biotechnology company Glycomine is finding deep-pocketed support from investors including Danish pharmaceutical giant Novo Nordisk.  The San Carlos, California company announced recently that it raised $33 million for its  experimental therapy for PMM2-CDG (CDG-1a), […]

To read the full article

OR